Pharmaceutical giant Astra Zeneca is considering moving its primary listing of the share from the London to the New York stock exchange, reports the British The Times. According to the newspaper, the CEO Pascal Soriot is frustrated with the British regulations, including restrictions regarding new medicines as well as pricing of medicines.
Astra Zeneca is listed on the London stock exchange as well as on its equivalent in Stockholm. Today's information made the share at closing have risen by just over 2 percent.
